JWJ-01-378
JWJ-01-378 is a selective TRK PROTAC degrader. JWJ-01-378 efficiently degrades WT TRK and TPM3-TRKA fusion proteins and inhibits downstream pERK signaling, while showing limited efficacy against TRK inhibitor resistant mutants and ALK fusions. JWJ-01-378 potently suppresses cancer cell proliferation[1].Pink: TRK ligand ; Blue: CRBN ligase ligand (HY-103596) ; Black: linker
Product Specifications
UNSPSC
12352005
Target
ERK; PROTACs; Trk Receptor
Related Pathways
MAPK/ERK Pathway; Neuronal Signaling; PROTAC; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=C(NCCCCCCCCNC(CN1CCN(CC1)C2=CC(NC3CCOCC3)=C(C=C2)C(NC4=NNC5=C4C=C(C=C5)CC6=CC(F)=CC(F)=C6)=O)=O)COC7=C8C(N(C(C8=CC=C7)=O)C9CCC(NC9=O)=O)=O
Molecular Formula
C55H62F2N10O9
Molecular Weight
1045.14
References & Citations
[1]Kumar S, et al. Development of PROTACs for targeted degradation of oncogenic TRK fusions. bioRxiv [Preprint]. 2025 Jun 24:2025.06.18.660465.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ATRX / RAD54 (Alpha Thalassemia Mental Retardation) (23c), CF647 conjugate, 0.1mg/mL
GATA-3 (Breast and Urothelial Marker) (GATA3/2688), CF488A conjugate, 0.1mg/mL
